Concepedia

Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative

Lucinda Orsini, Marc L. Berger, William H. Crown, Gregory W. Daniel, Hans‐Georg Eichler, Wim Goettsch, Jennifer S. Graff, John Guerino, Páll Jónsson, Nirosha Mahendraratnam Lederer,

Value in Health · 2020 · 129 citations · 18 references

DOIFull text

Open access

Concepts

References

18

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A C Sterne, Miguel A. Hernán, Barnaby C Reeves et al. · BMJ · 2016 · 19K citations · Full text

, , +15

Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making

Marc L. Berger, Harold C. Sox, Richard J. Willke et al. · Value in Health · 2017 · 452 citations · Full text

, , +17

Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I

Marc L. Berger, Muhammad Mamdani, David C. Atkins et al. · Value in Health · 2009 · 410 citations

, , +17

Guidelines for good pharmacoepidemiology practices (GPP)

ISPE · Pharmacoepidemiology and Drug Safety · 2007 · 346 citations

, , +10

Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <scp>ISPOR‐ISPE</scp> Special Task Force on real‐world evidence in health care decision making

Marc L. Berger, Harold C. Sox, Richard J. Willke et al. · Pharmacoepidemiology and Drug Safety · 2017 · 344 citations · Full text

, , +17